Effective Data Integration for Intelli.b**

Somru Bioscience Inc.是一家新兴的生物技术公司，致力于为研究、诊断和治疗应用开发突破性的抗体技术。Somru正在进行的一个项目名为“Intelli.b”。在Intelli.b中，Somru试图使用基于抗体微阵列的方法来研究发起者和生物相似的药物，以了解涉及的蛋白质的3D结构。生物相似药物预计将成为昂贵的原创药物的廉价替代品。然而，生物相似开发过程中的主要障碍是如何以低成本的方式确保发起者与生物相似药物之间的相似性。Intelli.b的目标是提供一种相对廉价的技术来评估发起者和生物相似药物之间的生物相似性。具体地说，在Intelli.b中，Somru实验室将产生大量关于3D结构的数据。此外，Somru希望充分利用公开可用的3D蛋白质结构数据库进行比较。由于每个数据库采用的数据格式往往是独一无二的，如何整合来自不同来源的数据，包括Somru实验室的数据和来自不同数据库的数据，是一个具有挑战性的问题。在拟议的项目中，我们计划设计和实施一个数据集成方案，有效地集成来自各种不同来源的数据，用于Intellib的生物相似性研究。**

Somru Bioscience Inc. is an emerging biotechnology company dedicated to developing breakthrough antibody technologies for research, diagnostic and therapeutic applications. One of the projects that Somru is working on is called "Intelli.b". In Intelli.b, Somru attempts to use an antibody microarray- based approach to study the originator and biosimilar drug in order to understand the 3D structure of the involved proteins. Biosimilar drug is expected to be a cheaper alternative to the expensive originator drug. However, the major hurdle in the process of biosimilar development is how to ensure the similarity between the originator and biosimilar drug in a low-cost manner. The objective of Intelli.b is to provide a relatively-cheap technology to evaluate the biosimilarity between the originator and biosimilar drug. Specifically, in Intelli.b, a large volume of data about the 3D structure will be generated at the laboratory of Somru. Furthermore, Somru would like to fully utilize the publicly-available 3D protein structure data banks for comparison purposes. Since the data format adopted by each data bank tends to be unique, how to integrate the data from varied sources, including the data from Somru laboratory and that from different data banks, is a challenging problem. In the proposed project, we plan to design and implement a data integration scheme that effectively integrate the data from a variety of different sources for the biosimilarity study of Intelli.b. **